Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s ...
Elinzanetant belongs to a new class of drugs designed to target what is believed to be a key mechanism responsible for ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 millionRaises full year 2025 global revenue ...
The company has $400 million, enough cash to potentially build off results from an early-stage leukemia yet this quarter.
That subtle dark line across the back of the neck might seem just a skin-matter. We might think it is because the clothes we ...
Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...
Background/Aims The neuroprotective effect of nicotinamide (NAM) supplementation has been demonstrated in both animal models ...
Here’s what one woman wants others to know about moving forward with strength and hope after an early breast cancer diagnosis ...
McLaurin (quadriceps), who is listed out for Sunday's game against the Seahawks, could be at risk of being sidelined through the Commanders' Week 12 bye, Ian Rapoport of NFL Network reports. After ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback